862 related articles for article (PubMed ID: 23634720)
1. Botulinum toxin treatment for bladder dysfunction.
Santos-Silva A; da Silva CM; Cruz F
Int J Urol; 2013 Oct; 20(10):956-62. PubMed ID: 23634720
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
Prescrire Int; 2013 Jan; 22(134):12-3. PubMed ID: 23367677
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
5. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
Peyronnet B; Roumiguié M; Castel-Lacanal E; Guillotreau J; Malavaud B; Marque P; Rischmann P; Gamé X
Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
Chen YC; Kuo HC
Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
[TBL] [Abstract][Full Text] [Related]
8. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
[TBL] [Abstract][Full Text] [Related]
9. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.
Goessaert AS; Everaert KC
Expert Rev Neurother; 2012 Jul; 12(7):763-75. PubMed ID: 22853784
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
11. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
Kuo HC
Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967
[TBL] [Abstract][Full Text] [Related]
12. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
[TBL] [Abstract][Full Text] [Related]
16. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
[TBL] [Abstract][Full Text] [Related]
17. Intradetrusor onabotulinum-a toxin injections in children with therapy-resistant idiopathic detrusor overactivity. A retrospective study.
Ringoir A; Dhondt B; De Bleser E; Van Laecke E; Everaert K; Groen LA; Hoebeke P; Spinoit AF
J Pediatr Urol; 2020 Apr; 16(2):181.e1-181.e8. PubMed ID: 31964616
[TBL] [Abstract][Full Text] [Related]
18. Use of botulinum toxin for genitourinary conditions: What is the evidence?
da Silva CM; Chancellor MB; Smith CP; Cruz F
Toxicon; 2015 Dec; 107(Pt A):141-7. PubMed ID: 26235907
[TBL] [Abstract][Full Text] [Related]
19. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
20. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?
Kessler TM; Danuser H; Schumacher M; Studer UE; Burkhard FC
Neurourol Urodyn; 2005; 24(3):231-6. PubMed ID: 15747344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]